$GNTA News
Last published 1w ago
- 1w agoGNTASAENGenenta Unveils Saentra Forge as Its New Brand, Advancing Its Transformation into a Strategic Industrial PlatformGlobeNewswireMILAN, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) (the "Company") today announced that it will do business as Saentra Forge and that its American Depositary Shares ("ADSs")
- 3w agoGNTAGenenta Science Announces Receipt of Nasdaq Minimum Bid Price Deficiency NotificationGlobeNewswireMILAN, Italy, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) (the "Company") today announced that on October 16, 2026, it received a notification letter from the Listing Qualifications
- 1mo agoGNTASòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into OrbitGlobeNewswireThe Spring Assembly manufactured by Sòphia HT, a strategic Genenta investment, supports the separation of the launcher’s second and third stages Sòphia HT has been in serial production of the component since 2018
- 3mo agoGNTAGenenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic ArmGlobeNewswireMILAN and NAPLES, Italy, July 23, 2026 (GLOBE NEWSWIRE) -- Sòphia High Tech S.r.l. (Sòphia HT), an Italian aerospace and defense company manufacturing critical parts for Europe's space and defense programs, backed
- 3mo agoGNTAGenenta-Backed Sòphia High Tech Reports Fiscal Year 2025 ResultsGlobeNewswireFiscal Year 2025 Highlights FY2025 sales rose 29.3% to €7.17 million; total value of production increased 34.7% to €8.47 millionEBITDA grew 68.1% to €1.61 million, expanding the EBITDA margin by approximately 380 basis
- 6mo agoGNTAGenenta signs Definitive Agreements with Sophia High TechGlobeNewswireMILAN,Italy, April 23, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian
- 7mo agoGNTAGenenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programsGlobeNewswireMILAN, March 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian
- 7mo agoGNTAGenenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi NaldiniGlobeNewswireMILAN, March 24, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) transforming to Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian
- 8mo agoGNTASAENGenenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia UniversityGlobeNewswireMILAN, March 13, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) transforming to Saentra Forge (NASDAQ:SAEN)1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian
- 8mo agoGNTASAENGenenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation PlatformGlobeNewswireMILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) in transformation to Saentra Forge (NASDAQ:SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace, and
- 9mo agoGNTASAENGenenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial ConsolidatorGlobeNewswireBuilding on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian CompaniesATC - a Defense-Sector Company: First Industrial
- 10mo agoGNTAGenenta Science Provides Update on CEO OwnershipGlobeNewswireMILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors, provides an update
- 11mo agoGNTAGenenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) TrialGlobeNewswireMILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic payloads in
- 1y agoGNTAGenenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary SharesGlobeNewswireMILAN and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology, today announced that it has entered into a securities purchase agreement with institutional investors
- 1y agoGNTAGenenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA ProductionGlobeNewswireMILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today announced a
- 1y agoGNTAGenenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival SignalsGlobeNewswireMILAN and NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology, today announced that a total of 38 patients were enrolled in newly diagnosed glioblastoma multiforme
- 1y agoGNTAGenenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapiesGlobeNewswireMILAN and NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a collaboration with Anemocyte, a leading
- 1y agoGNTAGenenta Showcases Strategic Vision at Premier Biotech Forum in QatarGlobeNewswireMILAN and NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Pierluigi Paracchi, CEO Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at "Montalcini Global
- 1y agoGNTAGenenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival RatesGlobeNewswireMILAN and NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, today announced a €20 million ($21.9 million) financing
- 1y agoONCYCELCGNTASLS+1Oncology Breakthroughs: How Cancer Research Is Advancing in 2025PR NewswireUSA News Group News Commentary – Now that World Cancer Day (Feb. 4) has come and gone, the world and the market are looking towards what's being...
- 1y agoGNTAGenenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy ManufacturingGlobeNewswireMILAN and NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that it has strengthened its partnership
- 1y agoGNTAITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCEPR NewswireTo promote investment opportunities in Italy in 2025, the Italian Trade Agency (ITA) and the Ministry of Foreign Affairs and International...
- 2y agoGNTAGenenta's CEO to present at the U.S. Senate meeting on "Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective"GlobeNewswireMILAN and NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and in cell-based therapeutics, is pleased to announce that Pierluigi Paracchi, CEO, will attend as a
- 2y agoGNTAGenenta Secures Approval for Innovative Trial for Metastatic Renal Cell CancerGlobeNewswireMILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the Agenzia Italiana del Farmaco
- 2y agoARYDGNTAGenenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd WiderGlobeNewswireMILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to
- 2y agoGNTAGenenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid TumorsGlobeNewswireMILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of hematopoietic stem
- 3y agoGNTAGenenta to Present at Upcoming Scientific and Investor ConferencesGlobeNewswireMILAN, Italy and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA) a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem
- 3y agoGNTAGenenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor TreatmentsGlobeNewswireCompany Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a
- 3y agoGNTAThe European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of GliomaGlobeNewswireMILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to
- 3y agoGNTAGenenta to Provide Update on Lead Product Temferon™GlobeNewswireMILAN, Italy and NEW YORK, May 16, 2023 (GLOBE NEWSWIRE) -- Luigi Naldini, Ph.D., M.D., co-founder and Executive Scientific Board Chairman of Genenta Science S.p.A. (NASDAQ:GNTA), a clinical-stage immuno-oncology
- 3y agoGNTAGenenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F FilingGlobeNewswireFunds available expected to be sufficient for Genenta to continue to operate into the first quarter of 2025Net exchange rate gain of €2.3 millionTax credit of €6.4 million MILAN, Italy and NEW YORK, April 26, 2023
- 3y agoGNTAGenenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor IndicationsGlobeNewswireMILAN, Italy and NEW YORK, April 03, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to
- 3y agoGNTAFDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma MultiformeGlobeNewswireMILAN and NEW YORK, March 02, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to
- 3y agoGNTAGenenta Science and AGC Biologics Enter Development and Manufacturing Service AgreementGlobeNewswireMILAN, N.Y., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company engaged in the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, has
- 3y agoAGRXGNTANMTRPGCorium Pharma Solutions Appoints Mark Sirgo as Chief Executive OfficerBusiness WireCorium Pharma Solutions, Inc. ("Corium Pharma Solutions" or "CPSI"), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies, including transdermal
- 4y agoGNTAGenenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma PatientsGlobeNewswire• Signs of intra-tumor pro-inflammatory state in patients• Temferon™ induced immune system reset in preclinical studies• Macrophage and T cell profiles in patients' tumor microenvironment echo preclinical findings
- 4y agoGNTABDSIGenenta Provides First Half 2022 Business Update and Financial ResultsGlobeNewswireCurrent dose escalation study data shows a median overall survival of 17 monthsAdding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimenCash and cash equivalents of €34.7 million as of June 30,
- 4y agoGNTAGenenta to Present at Upcoming Scientific and Investor ConferencesGlobeNewswireMILAN, Italy and NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatm
- 4y agoGNTAGenenta to Present at Upcoming Investor ConferencesGlobeNewswireMILAN, Italy and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical stage immune-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treat
- 4y agoGNTAAmCham Italy and Genenta Science Announce the Bowling Green Bull InitiativeGlobeNewswireMILAN, Italy, July 25, 2022 (GLOBE NEWSWIRE) -- Bowling Green Bull (BGB) is an initiative to connect Italian companies, entrepreneurs and top managers aiming for international growth and expansion in their interactions with U.S. financial markets and i
- 4y agoGNTAGenenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHAGlobeNewswireMILAN, Italy and NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will be presenting at sev
- 4y agoGNTAGenenta Appoints Industry Veteran Tim Obara as Head of Business DevelopmentGlobeNewswireMILAN, Italy and NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces the appointment
- 4y agoGNTAGenenta Files Annual Report on Form 20-F for Fiscal Year 2021GlobeNewswireMILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, today announced it
- 4y agoGNTAGenenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma MultiformeGlobeNewswireNo dose limiting toxicity observed in previous three dose level cohortsRepresents a 50% higher dose than highest prior levelUpdate of guidance for trial MILAN, Italy and NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a
- 4y agoGNTAGenenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in GlioblastomaGlobeNewswireMILAN, Italy and NEW YORK, May 02, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces that preliminar
- 4y agoBDSIGNTAGenenta Announces Nomination of Mark A. Sirgo as ChairGlobeNewswire35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnolo
- 4y agoGNTAGenenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid TumorsGlobeNewswireMILAN, Italy and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced it will hold
- 4y agoGNTAGenenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma MultiformeGlobeNewswireMILAN, Italy and NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, will present clinical d
- 4y agoGNTAGenenta to Participate at Upcoming Investor ConferencesGlobeNewswireMILAN, Italy and NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer (Temferon™), announced
- 4y agoGNTAGenenta Closes Its Upsized Initial Public Offering of American Depository SharesGlobeNewswireMILAN, Italy and NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including t